Abstract:The Receptor for Advanced Glycation End Products (RAGE) is expressed by multiple cell types in the brain and spinal cord that are linked to the pathogenesis of neurovascular and neurodegenerative disorders, including neurons, glia (microglia and astrocytes) and vascular cells (endothelial cells, smooth muscle cells and pericytes). Mounting structural and functional evidence implicates the interaction of the RAGE cytoplasmic domain with the formin, Diaphanous1 (DIAPH1), as the key cytoplasmic hub for RAGE ligand-mediated activation of cellular signaling. In aging and diabetes, the ligands of the receptor abound, both in the central nervous system (CNS) and in the periphery. Such accumulation of RAGE ligands triggers multiple downstream events, including upregulation of RAGE itself. Once set in motion, cell intrinsic and cell-cell communication mechanisms, at least in part via RAGE, trigger dysfunction in the CNS. A key outcome of endothelial dysfunction is reduction in cerebral blood flow and increased permeability of the blood brain barrier, conditions that facilitate entry of activated leukocytes into the CNS, thereby amplifying primary nodes of CNS cellular stress. This contribution details a review of the ligands of RAGE, the mechanisms and consequences of RAGE signal transduction, and cites multiple examples of published work in which RAGE contributes to the pathogenesis of neurovascular perturbation. Insights into potential therapeutic modalities targeting the RAGE signal transduction axis for disorders of CNS vascular dysfunction and neurodegeneration are also discussed.

Investigation of N-Glycan Functions in Receptor for Advanced Glycation End Products V Domain through Chemical Glycoprotein Synthesis

Imaging of protein-specific glycosylation by glycan metabolic tagging and in situ proximity ligation.

Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective

A versatile method for functionalizing surfaces with bioactive glycans.

Receptor for Advanced Glycation End Products (RAGE): A Pivotal Hub in Immune Diseases

Molecular Characteristics of RAGE and Advances in Small-Molecule Inhibitors

Survey of the Distribution of A Newly Characterized Receptor for Advanced Glycation End-Products in Tissues

Solution Structure of the Soluble Receptor for Advanced Glycation End Products (sRAGE)

Development of Receptor for Advanced Glycation End Products (RAGE) ligands through target directed dynamic combinatorial chemistry: a novel class of possible antagonists

Pathophysiology of RAGE in inflammatory diseases

Small Molecule Inhibition of Ligand-Stimulated RAGE-DIAPH1 Signal Transduction

Inhibition of RAGE Axis Signaling: A Pharmacological Challenge

A Computational and Chemical Design Strategy for Manipulating Glycan‐Protein Recognition

Investigation of the Catalytic Mechanism of a Soluble N-glycosyltransferase Allows Synthesis of N-glycans at Noncanonical Sequons.

Site-specific Chemoproteomic Profiling of Targets of Glyoxal

The Receptor for Advanced Glycation End Products (RAGE) and DIAPH1: Implications for vascular and neuroinflammatory dysfunction in disorders of the central nervous system

Selective N-glycan editing on living cell surfaces to probe glycoconjugate function

Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications

Tetrahedral Framework Nucleic Acids Based Small Interfering RNA Targeting Receptor for Advanced Glycation End Products for Diabetic Complications Treatment

Chemical Synthesis And Engineering Of N-Linked Glycoproteins

Efficient purification of soluble receptor for advanced glycation end-products from Sus scrofa lung tissue and synthesis of its binding ligand, glycated bovine serum albumin